A5074552399- Diabetes Treatment and Management
- Chronic Kidney Disease and Diabetes
- Acute Kidney Injury Research
- Hormonal Regulation and Hypertension
- Adrenal and Paraganglionic Tumors
- Diabetes Management and Research
- Blood Pressure and Hypertension Studies
- Potassium and Related Disorders
- Adrenal Hormones and Disorders
- Dialysis and Renal Disease Management
- Pancreatic function and diabetes
- Parathyroid Disorders and Treatments
- Cardiac Arrest and Resuscitation
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Magnesium in Health and Disease
- Heart Failure Treatment and Management
- Atrial Fibrillation Management and Outcomes
- Renal function and acid-base balance
- Cardiac, Anesthesia and Surgical Outcomes
- Metabolism, Diabetes, and Cancer
- Neurological and metabolic disorders
- Renal Transplantation Outcomes and Treatments
- Thyroid and Parathyroid Surgery
- Natural Products and Biological Research
- Autism Spectrum Disorder Research
Chi Mei Medical Center
2020-2025
Chia Nan University of Pharmacy and Science
2022-2025
Taipei Medical University
2024
University of California, Irvine
2022
National Chung Hsing University
2021
National Tsing Hua University
2016
Tamkang University
2012
Importance Sodium-glucose cotransport protein 2 inhibitors (SGLT-2is) have demonstrated associations with positive kidney-related and cardiovascular outcomes in patients type diabetes. However, the association of SGLT-2is among diabetes acute kidney disease (AKD) remains unclear. Objective To examine long-term mortality, major adverse events (MAKEs), (MACEs) AKD. Design, Setting, Participants This cohort study used global health care data (the TriNetX database) spanning from September 30,...
Importance Despite its demonstrated benefits in improving cardiovascular risk profiles, the association of tirzepatide with mortality and kidney outcomes compared glucagon-like peptide 1 receptor agonists (GLP-1 RAs) remains unknown. Objective To investigate adverse GLP-1 RAs patients type 2 diabetes. Design, Setting, Participants This retrospective cohort study used US Collaborative Network TriNetX data collected on individuals diabetes aged 18 years or older initiating RA between June 1,...
Abstract Previous studies have explored the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing cardiovascular events type 2 diabetes. Here we show that GLP-1 RAs are associated with lower risks mortality, major (MACEs), and adverse kidney (MAKEs) diabetes patients acute disease (AKD). Utilizing global data from TriNetX database (2002/09/01-2022/12/01) propensity score matching, compare 7511 users to non-users among 165,860 AKD patients. The most common causes AKI...
This article provides a thorough overview of the biomarkers, pathophysiology, and molecular pathways involved in transition from acute kidney injury (AKI) disease (AKD) to chronic (CKD). It categorizes biomarkers AKI into stress, damage, functional markers, highlighting their importance early detection, prognosis, clinical applications. review also highlights links between renal pathophysiological mechanisms underlying AKD, including hypoperfusion, sepsis, nephrotoxicity, immune responses....
Periodontal defects present a significant challenge in dentistry, necessitating innovative solutions for comprehensive regeneration. Traditional restoration methods have inherent limitations achieving complete and functional periodontal tissue reconstruction. Tissue engineering, multidisciplinary approach integrating cells, biomaterials, bioactive factors, holds tremendous promise addressing this challenge. Central to engineering strategies are scaffolds, pivotal supporting cell behavior...
Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) have demonstrated efficacy in improving mortality and cardiovascular (CV) outcomes. However, the impact of GLP-1RAs therapy on cardiorenal outcomes diabetic patients at commencement dialysis remains unexplored.
Abstract Background Sodium-glucose cotransporter 2 inhibitors (SGLT-2is) have demonstrated associations with lowering cardiovascular outcomes in patients type diabetes mellitus (T2DM). However, the impact of SGLT-2is on individuals at dialysis commencement remains unclear. The aim this real-world study is to association between and T2DM commencement. Methods This a retrospective cohort electronic health records (EHRs) from TriNetX Research Network database January 1, 2012, 2024. New-users...
Abstract Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) have demonstrated efficacy in reducing cardiovascular events and potentially improving kidney function diabetic patients. This investigation analyzes the TriNetX database to assess of SGLT-2i transplant recipients (KTR) concerning all-cause mortality, major adverse cardiac (MACE), (MAKE). The study includes type patients over 18 who underwent transplants between June 1, 2015, 2023, with a focus on use within first three months...
Abstract Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and finerenone each improve kidney cardiovascular outcomes in patients with chronic disease (CKD). This study compares the association between combined therapy versus monotherapy SGLT2i or kidney, cardiovascular, mortality CKD patients. Methods retrospective cohort included adults ≥18 years July 9, 2021, November 30, 2023 from multiple centers United States, utilizing TriNetX database. Exposures treatment finerenone,...
Immune checkpoint inhibitors (ICPi) have significantly improved survival for patients with advanced cancers. However, the occurrence of ICPi-associated acute kidney injury (AKI) and its clinical impact remains unclear. This study evaluates effects AKI (ICPi-AKI) on mortality, cardiovascular outcomes in undergoing ICPi treatments. multicentre retrospective cohort propensity score matching to balance baseline characteristics. The International Classification Diseases, 10th Revision codes were...
Abstract Background Cardiovascular disease is a leading cause of post-transplant mortality in kidney transplant recipients (KTRs), especially those with diabetes. Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated cardiovascular and benefits the general population type 2 diabetes mellitus (T2DM), evidence regarding their effects diabetic KTRs limited. Methods This retrospective cohort study utilized data from Global Collaborative Network TriNetX, spanning...